test

Why the Preserved Initial r Waves Are the Pathognomonic Discriminator: In left anterior fascicular block (LAFB), the initial depolarisation vector travels inferiorly and rightward through the intact left posterior fascicle before the delayed anterosuperior activation occurs. This preserved initial inferior vector generates a small r wave at the beginning of the QRS complex in leads II, III, and aVF, producing the characteristic rS pattern. This small r wave is the single most important morphological feature distinguishing LAFB from inferior myocardial infarction (IMI). In IMI, the necrosed inferior wall cannot generate initial forces, so the small r wave is replaced by pathological Q waves (QS or Qr pattern) in those same leads. The presence of initial r waves in the inferior leads proves that inferior myocardial tissue is electrically active and excludes significant inferior wall necrosis.

Electrophysiological Basis of the rS Pattern in LAFB: Understanding this requires knowledge of the sequential two-phase activation of the left ventricle in LAFB. Normally, both the anterior and posterior fascicles conduct simultaneously, and their vectors partially cancel. When the anterior fascicle is blocked, depolarisation begins exclusively through the posterior fascicle, directing the initial vector inferiorly and rightward (producing the small r in inferior leads and small q in leads I and aVL). After approximately 20 ms of delay, the wavefront spreads through working myocardium to reach the anterosuperior wall, generating a large leftward and superior vector (tall R in I and aVL, deep S in II, III, aVF). This two-phase activation—initial inferior, then dominant superior—creates the hallmark rS morphology and is the electrophysiological signature of LAFB.

Why Left Axis Deviation Alone Cannot Make This Distinction: Both LAFB and inferior MI produce left axis deviation—this is precisely why the axis alone is diagnostically insufficient. In LAFB, the LAD results from delayed superior activation of the anterosuperior wall. In inferior MI, the LAD results from loss of inferior electrical forces, leaving unopposed superior and leftward vectors. The magnitude of axis deviation (−45° versus −60°) does not reliably differentiate between the two conditions. Only the morphology of the initial QRS deflection in inferior leads (presence versus absence of the r wave) provides the definitive distinction. The 2009 AHA/ACCF/HRS scientific statement on ECG standardisation specifically identifies the rS versus Q-wave morphology in inferior leads as the diagnostically essential feature.

Complete LAFB Diagnostic Criteria Met in This Case: This ECG satisfies all recognised LAFB criteria: (1) Left axis deviation ≥−45° (axis is −45°). (2) rS pattern in leads II, III, and aVF with preserved initial r waves. (3) qR pattern in leads I and aVL (small q from preserved left-to-right septal depolarisation; tall R from delayed anterosuperior activation). (4) QRS duration of 100 ms (<120 ms), consistent with fascicular block (which prolongs QRS by only 10–40 ms, unlike complete bundle branch block which requires ≥120 ms). (5) No ST-T abnormalities. In a 40-year-old asymptomatic woman, isolated LAFB is a benign incidental finding requiring no further evaluation or treatment.

The “r Before S” Rule for LAFB vs Inferior MI: When you see left axis deviation with predominantly negative complexes in the inferior leads, the first and most important question is: does the QRS in leads II, III, and aVF begin with a small r wave? If yes (rS pattern) → LAFB (the inferior wall is alive and generating forces). If no (QS or Qr with pathological Q) → inferior MI (the inferior wall is necrosed and electrically silent). This single morphological observation is more diagnostically powerful than the degree of axis deviation, the QRS duration, or the presence of Q waves in lateral leads. Remember: “LAFB preserves the r; inferior MI destroys it.”

Clinical Implication: Isolated LAFB is benign and requires no treatment. However, LAFB combined with right bundle branch block (RBBB) constitutes bifascicular block, indicating disease in two of three fascicles. The 2018 ACC/AHA/HRS Bradycardia Guidelines recommend permanent pacemaker implantation (Class I) in patients with bifascicular block when syncope is attributable to heart block or when the HV interval is ≥70 ms on electrophysiology study (Class IIa). The left anterior fascicle is anatomically vulnerable because it is thin, long, and supplied by only the left anterior descending artery, while the posterior fascicle has a dual blood supply (LAD + RCA)—explaining why LAFB is approximately 30 times more common than left posterior fascicular block.

What Examiners Are Testing:

1. The LAFB vs Inferior MI Differential: This is the most commonly tested ECG differential involving fascicular blocks on board examinations. Examiners present LAD with negative complexes in inferior leads and ask candidates to identify the diagnosis and explain how they exclude inferior MI. The expected answer is always the preserved r wave in inferior leads—not the axis, not the QRS width, not the ST segments.

2. Understanding Why Each Feature Fails as a Discriminator: The difficulty of this question lies in recognising that all four incorrect options are genuine LAFB features—but none is the KEY differentiator. Many candidates select “degree of LAD” because they associate LAFB with extreme LAD. The trap is that inferior MI also produces extreme LAD, so axis alone cannot differentiate.

3. Fascicular Anatomy and Vulnerability: Knowing that the left anterior fascicle supplies the anterosuperior LV wall and the posterior fascicle supplies the inferior wall explains the rS pattern: the intact posterior fascicle generates the initial inferior r wave, and the blocked anterior fascicle causes the delayed superior S wave. Understanding the anatomy is the key to understanding the ECG.

4. Clinical Significance Awareness: Board questions may test that isolated LAFB is benign, but when combined with RBBB (“bifascicular block”) and/or first-degree AV block, it suggests extensive conduction system disease potentially requiring pacemaker evaluation per the 2018 ACC/AHA/HRS guidelines.

1. Surawicz B, Childers R, Deal BJ, Gettes LS. AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram: Part III: Intraventricular Conduction Disturbances. J Am Coll Cardiol. 2009;53(11):976–981. https://doi.org/10.1016/j.jacc.2008.12.013
2. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay. J Am Coll Cardiol. 2019;74(7):e51–e156. https://doi.org/10.1016/j.jacc.2018.10.044
3. Elizari MV, Acunzo RS, Ferreiro M. Hemiblocks Revisited. Circulation. 2007;115(9):1154–1163. https://doi.org/10.1161/CIRCULATIONAHA.106.637389
4. Goldberger AL, Goldberger ZD, Shvilkin A. Goldberger’s Clinical Electrocardiography: A Simplified Approach. 10th ed. Elsevier; 2024. Chapter 7: Intraventricular Conduction Disturbances.
5. Strauss DG, Schocken DD. Marriott’s Practical Electrocardiography. 13th ed. Wolters Kluwer; 2022. Chapter 5: Intraventricular Conduction Defects.

Electrophysiological Mechanism of Calcium in Hyperkalemia: In hyperkalemia, elevated extracellular potassium reduces the resting membrane potential (makes it less negative, from approximately −90 mV toward −60 mV), narrowing the gap between resting potential and threshold potential. This partial depolarization initially increases excitability but rapidly leads to sodium channel inactivation, slowing conduction velocity and producing the characteristic ECG changes (peaked T waves, widened QRS, loss of P waves). Intravenous calcium raises the threshold potential (shifts it to a more positive value), thereby restoring the gradient between resting and threshold potential without changing the resting membrane potential or serum potassium concentration.

Why This Is Called “Membrane Stabilization”: The term “membrane stabilization” specifically refers to calcium’s effect on the voltage-gated sodium channel activation threshold. By increasing the threshold potential, calcium makes myocytes less susceptible to depolarization from the abnormally elevated resting potential. This restores the normal safety margin for cardiac conduction. The effect is visible on ECG within 1–3 minutes as QRS narrowing and restoration of P waves. However, because calcium does not alter potassium concentration or redistribution, this protection is temporary (30–60 minutes), requiring concurrent potassium-lowering interventions.

Clinical Urgency Justifying First-Line Priority: The ECG findings in this patient—peaked T waves, PR prolongation to 240 ms, QRS widening to 140 ms, and loss of P waves—represent advanced cardiotoxicity that can degenerate into sine-wave pattern and ventricular fibrillation within minutes. Potassium-shifting agents (insulin, albuterol) require 15–30 minutes for onset. Calcium gluconate is the only intervention with an onset of 1–3 minutes, providing a critical bridge of cardiac protection while slower-acting therapies take effect. Per KDIGO consensus and the European Resuscitation Council, IV calcium is the immediate first step whenever ECG changes are present.

Distinction from Potassium-Lowering Mechanisms: Calcium gluconate operates through an entirely different pharmacological pathway than potassium-lowering agents. Insulin activates Na–K ATPase, shifting K+ intracellularly. Albuterol stimulates β2-receptors activating the same pump. Sodium bicarbonate promotes transcellular shift via H+/K+ exchange. Dialysis and binding resins remove K+ from the body. Calcium does none of these—it acts solely on the cardiac membrane to restore the threshold-to-resting potential gradient. Understanding this mechanistic distinction is critical because it explains why calcium must be followed by additional therapies.

The Hyperkalemia ECG Progression Sequence: Memorize this ordered sequence of ECG changes with rising potassium: (1) Peaked T waves (K+ 5.5–6.5) → (2) PR prolongation (K+ 6.5–7.0) → (3) P-wave flattening/loss (K+ 7.0–7.5) → (4) QRS widening (K+ 7.0–8.0) → (5) Sine-wave pattern (K+ >8.0) → (6) Ventricular fibrillation/asystole. This patient is at Stage 4—one step from sine wave and two steps from cardiac arrest. Remember: ECG changes may not follow this sequence in all patients, and sensitivity of ECG for hyperkalemia severity is limited, which is why KDIGO recommends treating based on potassium level >6.5 mEq/L regardless of ECG findings.

Clinical Implication: The emergency hyperkalemia treatment algorithm has three tiers: (1) Membrane stabilization—calcium gluconate IV (onset 1–3 min, does NOT lower K+); (2) Redistribution—insulin + dextrose and/or nebulized albuterol (onset 15–30 min, temporarily shift K+ intracellularly); (3) Elimination—hemodialysis, loop diuretics, or potassium binders (definitive removal from body). All three tiers should be initiated simultaneously, but calcium must be given first because it is the only intervention fast enough to prevent arrhythmia during the lag time before redistribution agents take effect.

What Examiners Are Testing:

1. Mechanistic Understanding Beyond Protocol Memorization: Most candidates know that calcium gluconate is given first in hyperkalemia with ECG changes. This question tests WHY—the underlying electrophysiology. Understanding that calcium raises the threshold potential (not lowering K+ or blocking channels) distinguishes candidates who understand the science from those who only memorized the algorithm.

2. Differentiation of Drug Mechanisms in Hyperkalemia: The distractors test whether the candidate can correctly assign mechanisms to specific drugs: insulin = Na-K ATPase, calcium = threshold potential restoration, Class III antiarrhythmics = K+ channel blockade. Confusing these mechanisms is a high-frequency error on board examinations.

3. Integration of ECG Recognition with Therapeutics: The ECG findings in the stem confirm advanced cardiotoxicity requiring immediate calcium. Examiners test whether the candidate recognizes the clinical urgency implied by loss of P waves and QRS widening, and understands why a drug that does not lower potassium is still the most urgent intervention.

4. Pharmacological Precision Under Pressure: The phrasing “despite not lowering serum potassium” is a deliberate test of careful reading. Two distractors (chelation, Na-K ATPase) describe mechanisms that would lower potassium—contradicting the question’s premise. Candidates who select these options are not reading the question stem carefully, a common board examination pitfall.

1. Lindner G, Burdmann EA, Clase CM, et al. Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference. Eur J Emerg Med. 2020;27(5):329–337. https://doi.org/10.1097/MEJ.0000000000000691
2. Rafique Z, Peacock WF, Engstrom-Melnyk J, et al. Hyperkalemia management in the emergency department: an expert panel consensus. J Am Coll Emerg Physicians Open. 2021;2(5):e12572. https://doi.org/10.1002/emp2.12572
3. Long B, Warix JR, Koyfman A. Controversies in management of hyperkalemia. J Emerg Med. 2018;55(2):192–205. https://doi.org/10.1016/j.jemermed.2018.04.004
4. Clase CM, Carrero JJ, Ellison DH, et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a KDIGO Controversies Conference. Kidney Int. 2020;97(1):42–61. https://doi.org/10.1016/j.kint.2019.09.018

Why Permanent Pacing Is a Class I Indication for Mobitz Type II: The 2018 ACC/AHA/HRS Guideline on Evaluation and Management of Bradycardia and Cardiac Conduction Delay assigns permanent pacemaker implantation a Class I (Level of Evidence B-NR) recommendation for second-degree Mobitz type II AV block, regardless of symptoms or hemodynamic status. This is one of the few conduction abnormalities where pacing is indicated even in the absence of documented symptomatic bradycardia. The rationale is that Mobitz II block reflects structural disease of the His-Purkinje system with a high risk of progression to complete heart block—often suddenly and without warning—which can result in asystole, syncope, and sudden cardiac death.

Recognizing the ECG Pattern – Mobitz Type II Block: The telemetry findings are pathognomonic for Mobitz type II second-degree AV block: (1) constant PR intervals in all conducted beats—no progressive prolongation; (2) sudden, unexpected failure of a P wave to conduct (dropped QRS) without prior Wenckebach periodicity; (3) wide QRS in conducted beats (RBBB with QRS 148 ms), indicating the block is below the AV node in the His-Purkinje system. The combination of Mobitz II + bundle branch block localizes the disease to the infranodal conduction system—the most dangerous site for conduction block because escape rhythms from this level are unreliable (wide complex, slow rate 20–40 bpm, hemodynamically unstable).

Why Dual-Chamber (DDD) Over Single-Chamber (VVI) Pacing: A dual-chamber (DDD) pacemaker is preferred over a single-chamber ventricular (VVI) device because it preserves AV synchrony—the coordinated contraction of atria before ventricles. The MOST trial (Lamas et al., 2002) and the CTOPP trial (Connolly et al., 2000) demonstrated that physiologic (dual-chamber or atrial) pacing reduces atrial fibrillation incidence and pacemaker syndrome compared with ventricular-only pacing. In this patient with intact sinus node function (normal P waves at a physiological rate), the atrium is generating normal impulses that simply cannot conduct through the diseased His-Purkinje system. DDD pacing senses atrial activity and paces the ventricle in synchrony, maintaining the hemodynamic benefit of atrial kick—which contributes approximately 15–25% of cardiac output, particularly important in older patients with diastolic dysfunction.

The Danger of Watchful Waiting in Infranodal Block: Unlike Mobitz type I (Wenckebach) block, which typically occurs at the AV nodal level and has a benign prognosis with reliable junctional escape rhythms (40–60 bpm, narrow complex), Mobitz type II block carries the risk of unpredictable progression to complete heart block. When complete block develops in an infranodal location, the escape rhythm originates from distal Purkinje fibers or ventricular myocardium—these escape rhythms are inherently slow (20–40 bpm), unreliable, and may fail entirely, resulting in prolonged asystole. Observation is therefore inappropriate regardless of the patient’s current hemodynamic stability, as the next event could be fatal.

The “Mobitz II = Pacemaker, Period” Rule: For board examinations, memorize this absolute principle: Mobitz type II second-degree AV block is a Class I indication for permanent pacemaker implantation regardless of symptoms. This is one of only a few conduction abnormalities where pacing is mandatory even in an asymptomatic patient. The key distinguishing features from Mobitz I: constant PR → sudden drop (not progressive prolongation), wide QRS (BBB pattern), and atropine-unresponsive. When you see these three features, proceed directly to permanent pacing—do not observe, do not trial atropine as definitive therapy.

Clinical Implication: In practice, the family physician’s role is to recognize Mobitz II on telemetry/ECG, avoid atropine, initiate temporary pacing if hemodynamically unstable, and arrange urgent cardiology consultation for permanent pacemaker implantation. Between recognition and pacemaker implantation, the patient should remain on continuous telemetry with transcutaneous pacing pads applied and ready. The median time from Mobitz II diagnosis to permanent pacer implantation should be <24–48 hours.

What Examiners Are Testing:

1. ECG Pattern Recognition – Mobitz I vs Mobitz II: The stem provides a classic Mobitz II description (constant PR + sudden dropped QRS + wide QRS). Candidates must differentiate this from Wenckebach (progressive PR prolongation + grouped beating + narrow QRS). This distinction drives completely different management: observation for asymptomatic Mobitz I vs mandatory pacemaker for Mobitz II.

2. Understanding “Definitive” vs “Temporizing” Management: The discriminating distractors are atropine, transcutaneous pacing, and isoproterenol—all legitimate temporizing measures that fail the “definitive” criterion. The question word “definitive” is the key signal that only permanent pacemaker implantation satisfies the question stem.

3. Atropine’s Limitation in Infranodal Block: This is high-yield board material: atropine works at the AV node (vagal innervation) but is ineffective below the AV node. Candidates who select atropine have failed to localize the block anatomically. This concept extends to ACLS algorithms where atropine is first-line for symptomatic bradycardia but explicitly not relied upon for Mobitz II.

4. The “Stable Patient” Trap: The stem deliberately states the patient is “hemodynamically stable between episodes” to tempt candidates into selecting observation. This tests the critical understanding that Mobitz II is never benign—stability is temporary and complete block with asystole can occur without warning. This is analogous to treating an aortic dissection regardless of current stability.

1. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay. Circulation. 2019;140(8):e382-e482. https://doi.org/10.1161/CIR.0000000000000628
2. Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy. Eur Heart J. 2021;42(35):3427-3520. https://doi.org/10.1093/eurheartj/ehab364
3. Lamas GA, Lee KL, Sweeney MO, et al. Ventricular Pacing or Dual-Chamber Pacing for Sinus-Node Dysfunction (MOST Trial). N Engl J Med. 2002;346(24):1854-1862. https://doi.org/10.1056/NEJMoa013040
4. Connolly SJ, Kerr CR, Gent M, et al. Effects of Physiologic Pacing Versus Ventricular Pacing on the Risk of Stroke and Death Due to Cardiovascular Causes (CTOPP Trial). N Engl J Med. 2000;342(19):1385-1391. https://doi.org/10.1056/NEJM200005113421902
5. Panchal AR, Bartos JA, Cabañas JG, et al. Part 3: Adult Basic and Advanced Life Support: 2020 AHA Guidelines for CPR and ECC. Circulation. 2020;142(16_suppl_2):S366-S468. https://doi.org/10.1161/CIR.0000000000000916

Why a Dihydropyridine CCB Is the Guideline-Recommended Second Agent: The 2023 AHA/ACC Chronic Coronary Disease (CCD) Guideline provides a clear stepped approach to antianginal therapy. For patients with persistent angina despite initial treatment with a beta-blocker, addition of a second antianginal agent from a different therapeutic class is recommended (Class 1, LOE B-R). The three first-line antianginal classes are beta-blockers, calcium channel blockers (CCBs), and long-acting nitrates. Since this patient is already on a beta-blocker, the most appropriate addition is a long-acting dihydropyridine (DHP) CCB such as amlodipine. Amlodipine provides complementary antianginal benefit through coronary and peripheral vasodilation, increasing myocardial oxygen supply while reducing afterload, without the dangerous additive AV nodal suppression seen with non-DHP CCBs.

Why DHP-CCBs Are Safe With Beta-Blockers While Non-DHP CCBs Are Not: This distinction is the core pharmacological principle being tested. DHP-CCBs (amlodipine, nifedipine, felodipine) act primarily on vascular smooth muscle, causing vasodilation with minimal effects on cardiac conduction. They are safe and synergistic when combined with beta-blockers. In contrast, non-DHP CCBs (diltiazem, verapamil) act primarily on cardiac myocytes, suppressing SA node automaticity and AV node conduction (negative chronotropic and dromotropic effects). Combining a non-DHP CCB with a beta-blocker creates additive suppression of the cardiac conduction system, risking severe bradycardia, high-degree AV block, hemodynamic collapse, and even cardiac arrest. This patient’s resting heart rate of 58 bpm already indicates significant beta-blockade, making non-DHP CCB addition particularly dangerous.

Why Starting Amlodipine 5 mg Is Appropriate Despite BP 118/72: Although the patient’s blood pressure is in the low-normal range, amlodipine 5 mg is appropriate as a starting dose. Amlodipine typically reduces systolic BP by 5–10 mmHg, which would bring this patient to approximately 108–113/65–70 mmHg—still within a tolerable hemodynamic range. Amlodipine has a long half-life (~30–50 hours) providing stable, gradual vasodilation without sharp BP drops. Its antianginal effect is achieved through coronary vasodilation and reduced myocardial oxygen demand, not solely through BP reduction. The patient should be counseled about dizziness and monitored with a follow-up BP check in 1–2 weeks.

Where Ranolazine Fits in the Stepped Algorithm: Per the 2023 AHA/ACC CCD Guideline, ranolazine is recommended for patients who remain symptomatic DESPITE treatment with beta-blockers, CCBs, or long-acting nitrates (Class 1, LOE B-R). This means ranolazine is positioned as a third-line addition, not a second-line agent. This patient has not yet received a trial of a CCB in combination with his beta-blocker. While ranolazine is hemodynamically neutral (does not lower HR or BP significantly), it should be reserved for patients whose symptoms persist after optimizing first-line combination therapy. Jumping to ranolazine before adding a CCB is premature and skips a guideline-recommended step.

The “DHP = Dihydropyridine = Dilates vessels” Rule: When adding a CCB to a beta-blocker, always choose a dihydropyridine (amlodipine, nifedipine, felodipine) because they act on vascular smooth muscle, not on the cardiac conduction system. The mnemonic: “DHP dilates; non-DHP depresses”—DHP-CCBs dilate vessels while non-DHP CCBs (diltiazem, verapamil) depress cardiac conduction. Combining two drugs that both suppress AV node conduction (BB + non-DHP CCB) creates a life-threatening synergy of bradycardia and heart block. The 2023 AHA/ACC antianginal stepped algorithm: BB → add DHP-CCB → add ranolazine or long-acting nitrate → consider revascularization if refractory.

Clinical Implication: In primary care, the most common error is prescribing diltiazem to a patient already on a beta-blocker. Always verify the CCB subclass before prescribing. When you see the suffix “-dipine” (amlodipine, nifedipine, felodipine), it is a DHP and safe with beta-blockers. When you see “diltiazem” or “verapamil,” these are non-DHPs and should not be combined with beta-blockers unless under very close monitoring in rare, specific situations.

What Examiners Are Testing:

1. DHP vs. Non-DHP CCB Pharmacology: This is a core board concept. Examiners expect candidates to know that DHP-CCBs act on vessels (safe with BB) while non-DHP CCBs act on the heart (dangerous with BB). The diltiazem option is designed to trap candidates who think “add a CCB” without distinguishing the subclass.

2. Interpreting Hemodynamic Clues in the Stem: The HR of 58 bpm and BP of 118/72 are deliberate signals. They tell you: (a) beta-blocker is adequately dosed (cannot increase), (b) BP limits but does not preclude a vasodilator, and (c) non-DHP CCB is especially dangerous at this HR. Examiners test whether candidates use vital signs to guide therapy.

3. Guideline Stepped-Therapy Sequence: The ranolazine distractor tests whether candidates know the correct sequence: first-line agents (BB, CCB, nitrate) must be combined before adding ranolazine. Skipping ahead to ranolazine, however appealing due to its neutral hemodynamic profile, is not guideline-concordant.

4. COURAGE/ISCHEMIA Trial Principles: The angiography distractor tests understanding that revascularization does not reduce MACE beyond optimal medical therapy in stable CCD. Medical therapy must be fully optimized before considering invasive strategies, except in left main disease, severely reduced LVEF, or truly refractory symptoms.

1. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. Circulation. 2023;148(24):e218-e309. https://doi.org/10.1161/CIR.0000000000001168
2. Boden WE, O’Rourke RA, Teo KK, et al. Optimal Medical Therapy with or without PCI for Stable Coronary Disease (COURAGE). N Engl J Med. 2007;356(15):1503-1516. https://doi.org/10.1056/NEJMoa070829
3. Maron DJ, Hochman JS, Reynolds HR, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease (ISCHEMIA). N Engl J Med. 2020;382(15):1395-1407. https://doi.org/10.1056/NEJMoa1915922
4. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of Ranolazine with Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients with Severe Chronic Angina (CARISA). JAMA. 2004;291(3):309-316. https://doi.org/10.1001/jama.291.3.309
5. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes. Eur Heart J. 2020;41(3):407-477. https://doi.org/10.1093/eurheartj/ehz425